Oxford Nanopore Technologies Ltd - Asset Resilience Ratio
Oxford Nanopore Technologies Ltd (ONT) has an Asset Resilience Ratio of 7.45% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Oxford Nanopore Technologies Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how Oxford Nanopore Technologies Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Oxford Nanopore Technologies Ltd.
Liquid Assets Composition Over Time
This chart breaks down Oxford Nanopore Technologies Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Oxford Nanopore Technologies Ltd (ONT) total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX42.10 Million | 7.45% |
| Total Liquid Assets | GBX42.10 Million | 7.45% |
Asset Resilience Insights
- Limited Liquidity: Oxford Nanopore Technologies Ltd maintains only 7.45% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Oxford Nanopore Technologies Ltd Industry Peers by Asset Resilience Ratio
Compare Oxford Nanopore Technologies Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Pulike Biological Engineering
SHG:603566 |
Biotechnology | 17.82% |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 14.00% |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5 |
Biotechnology | 41.67% |
|
Upstream Bio, Inc.
NASDAQ:UPB |
Biotechnology | 64.70% |
Annual Asset Resilience Ratio for Oxford Nanopore Technologies Ltd (2012–2025)
The table below shows the annual Asset Resilience Ratio data for Oxford Nanopore Technologies Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 11.92% | GBX74.20 Million ≈ $9.03K |
GBX622.50 Million ≈ $75.74K |
-6.79pp |
| 2024-12-31 | 18.71% | GBX138.85 Million ≈ $16.89K |
GBX742.05 Million ≈ $90.29K |
+12.34pp |
| 2023-12-31 | 6.37% | GBX49.51 Million ≈ $6.02K |
GBX777.06 Million ≈ $94.55K |
-8.12pp |
| 2022-12-31 | 14.49% | GBX119.41 Million ≈ $14.53K |
GBX823.89 Million ≈ $100.24K |
-1.02pp |
| 2021-12-31 | 15.52% | GBX130.63 Million ≈ $15.89K |
GBX841.87 Million ≈ $102.43K |
-17.59pp |
| 2018-12-31 | 33.11% | GBX58.00 Million ≈ $7.06K |
GBX175.19 Million ≈ $21.32K |
+24.73pp |
| 2017-12-31 | 8.38% | GBX10.00 Million ≈ $1.22K |
GBX119.31 Million ≈ $14.52K |
-29.37pp |
| 2016-12-31 | 37.75% | GBX60.00 Million ≈ $7.30K |
GBX158.94 Million ≈ $19.34K |
-3.67pp |
| 2015-12-31 | 41.42% | GBX45.06 Million ≈ $5.48K |
GBX108.77 Million ≈ $13.23K |
-9.96pp |
| 2014-12-31 | 51.38% | GBX36.12 Million ≈ $4.39K |
GBX70.30 Million ≈ $8.55K |
+3.24pp |
| 2013-12-31 | 48.14% | GBX33.15 Million ≈ $4.03K |
GBX68.87 Million ≈ $8.38K |
+3.77pp |
| 2012-12-31 | 44.37% | GBX23.05 Million ≈ $2.80K |
GBX51.95 Million ≈ $6.32K |
-- |
About Oxford Nanopore Technologies Ltd
Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows analysis of DNA or RNA. The company offers MinION Mk 1D, a portable device for DNA and RNA sequencing; and GridION and GridION Q, a compact bench top device that delivers a version… Read more